Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > Screening Study for Men at High Genetic Risk for Prostate Cancer
Glossary on
off
Printer Friendly Page Screening Study for Men at High Genetic Risk for Prostate Cancer

Screening Study for Men at High Genetic Risk for Prostate Cancer

Clinicaltrials.gov identifier:
NCT03805919

Prevention
Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation

Study Contact Information:

Anna Couvillon, Nurse Practitioner
By phone: (240) 858-3148
or by email 


Screening Study for Men at High Genetic Risk for Prostate Cancer

About the Study

The National Cancer Institute opened a clinical trial for cancer screening in men who are at high risk for cancer due to an

View the study on ClinicalTrials.gov or contact Anna Couvillon, NP at: (240) 858-3148 or by email. 

What the Study Entails

  • Screening of the every 2 years
  • Annual blood test
  • Biopsy of the if any MRIs are abnormal
  • No cost for study-related tests or procedures
  • No cost for travel
  • Clinical information will be shared with you and your doctor, if you choose
  • Genetic testing is not offered as part of the study

Study Lead Investigator

Fatima Karzai, MD, National Cancer Institute (NCI)

Study Site

The National Institutes of Health (), Clinical Center
Bethesda, MD in the Washington, DC metro area
NIH can cover the cost of travel for participants

 

This Study is Open To:

Men, and people assigned male at birth are eligible if they:

  • are between the ages 30 - 75 years old
  • do not have  cancer, and 
  • have had genetic testing and have any of the following: (, , , , ), , , , , , , , , , , , or FANC (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, and FANCM) mutation.
This Study is Not Open To:
  • People who have already been diagnosed with cancer